Русский
Search Articles by Keyword
Found: 72 articles
| Article | Edition |
|---|---|
|
Bekkeldieva N.B., Semiglazov V.F., Kudaibergenova A.G., Emelyanov A.S., Nikolaev K.S., Mortada V.V., Zernov K.Yu., Raimzhanov Ch.A., Tabagua T.T., Pesotsky R.S., Bondarchuk Ya.I., Amirov N.S., Enaldieva D.A., Ulrikh D.G., Levchenko V.E., Krivorotko P.V.
Prognostic value of low HER2 expression in patients with early breast cancer
|
№3 / 2025 |
|
I.I. Amergulov, M.G. Pavlova, Yu.P. Sych, Yu.R. Zhuravleva, M.M. Dolov, M.T. Berdyklychev, V.Z. Dobrokhotova, E.O. Sannikova, O.P. Trofimova, M.V. Orlova, D.A. Kuznetsova, N.M. Bychkova, N.A. Zaitseva, E.Yu. Kandakova, V.M. Sotnikov, E.G. Ryzhkova, V.V. Fadeev
Structural and functional changes in the thyroid gland in the early and late periods after radiation therapy
|
№2 / 2025 |
|
Bagdasaryan A.A., Shikh E.V., Drozdov V.N.
The influence of CYP3A5, CYP2D6, CYP2C19 and ABCB1 gene polymorphisms on the levels of minimum steady-state concentration of doxorubicin and troponin I in patients with breast cancer: an observational cross-sectional study
|
№9 / 2024 |
|
Gordeeva O.O., Bokova S.E.
Adherence to adjuvant hormonal therapy for luminal HER2-negative breast cancer: results of a patient survey
|
№6 / 2024 |
|
Gordeeva O.O.
Assessing the risk of recurrence of luminal HER2-negative breast cancer and the possibility of intensifying adjuvant hormonal therapy to reduce the risk of progression
|
№6 / 2024 |
|
V.F. Semiglazov, P.V. Krivorotko, N.B. Bekkeldieva, A.V. Komyakhov, A.S. Emelyanov, A.O. Gorina
The role of cyclin-dependent kinase inhibitors in adjuvant therapy of breast cancer
|
№14 / 2023 |
|
V.F. Semiglazov, P.V. Krivorotko, N.B. Bekkeldieva, A.O. Gorina, A.V. Komyakhov, R.M. Paltuev, T.T. Tabagua, S.S. Ereshenko
Trastuzumab deruxtecan in the treatment of breast cancer
|
№11 / 2023 |
|
G.A. Dashyan, E.S. Dzhelialov, V.V. Konstantinova, Yu.A. Gronskaya, A.D. Murskikh, R.M. Akhmedov, A.E. Tyusenko, A.A. Olchonova, Z.V. Dyakonenko, O.A. Sereda, A.M. Belousov
Primary resistance to anti-HER2 therapy: mechanisms of development and ways to overcome
|
№11 / 2023 |
|
R.V. Orlova, M.I. Gluzman, A.A. Vakhitova
Possibilities of overcoming hormone resistance in patients with metastatic HR+ HER2- breast cancer using the drug alpelisib in various subgroups in real clinical practice
|
№11 / 2023 |
|
I.S. Gulian, E.P. Bystritskaya, N.Yu. Otstavnykh, E.V. Khudchenko, E.V. Eliseeva, V.I. Apanasevich, M.P. Isaeva
GSTT1 and GSTM1 deletion polymorphism as a predictor of response to hormonal therapy for breast cancer
|
№11 / 2023 |
|
G.A. Dashyan, V.V. Konstantinova, E.S. Dzhelialov, R.M. Akhmedov, Yu.V. Semiletova, A.S. Zhurov, A.E. Tyusenko, A.A. Olchonova, I.A. Pavlikova, A.M. Belousov
Delay of initiation of adjuvant chemotherapy in patients with early breast cancer: causes and consequences
|
№11 / 2023 |
|
Sh.G. Khakimova, A.D. Zikiryakhodzhaev, A.D. Kaprin, G.G. Khakimova, I.M. Onofriychuk, E.A. Rasskazova, A.S. Sukhotko, M.Yu. Vlasova, A.R. Bosieva, V.K. Tokaev
Reconstructive plastic surgery of the breast using autogenous tissue. Historical aspects
|
№11 / 2023 |
